市场调查报告书
商品编码
1576662
ELISA 市场规模、占有率、预测和趋势分析:按类型、按技术和按应用/按最终用户 - 2031 年世界预测ELISA Market Size, Share, Forecast, & Trends Analysis by Type (Direct, Sandwich, Competitive) Offering (Analyzer, Software) Technology (Chemiluminescence, Colorimetry, Fluorescence) Application (Research, Diagnostic) End User - Global Forecast to 2031 |
预计到 2031 年,ELISA 市场将达到 326.9 亿美元,2024 年至 2031 年复合年增长率为 6.1%。
经过广泛的二次和初步研究以及对市场情景的详细分析,本报告对关键行业推动因素、阻碍因素、课题和机会进行了分析。ELISA 市场的成长是由慢性病和传染病的增加、ELISA 在临床环境中的使用增加、ELISA 的进步以及 ELISA 在食品行业中的使用增加所推动的。然而,假阳性的可能性和製备 ELISA 抗体的高成本限制了市场的成长。
此外,新兴国家研究的成长、生物标记检测研发活动的增加以及对疫苗开发的日益关注预计将为市场成长创造机会。然而,有关 ELISA 产品审批以及疾病诊断替代技术的可用性和利用的严格规定是 ELISA 市场的主要课题。
(註:前5名的企业提供SWOT分析)
ELISA Market Size, Share, Forecast, & Trends Analysis by Type (Direct, Sandwich, Competitive) Offering (Analyzer, Software) Technology (Chemiluminescence, Colorimetry, Fluorescence) Application (Research, Diagnostic) End User-Global Forecast to 2031
The ELISA market is projected to reach $32.69 billion by 2031 at a CAGR of 6.1% from 2024 to 2031.
Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report comprises the analysis of key industry drivers, restraints, challenges, and opportunities. The growth of the ELISA market is driven by the increasing number of chronic and infectious diseases, growing ELISA application in clinical settings, advancements in ELISA, and the growing application of ELISA in food industries. However, the chances of false positive results and high ELISA antibody preparation costs restrain the growth of this market.
Furthermore, growing research in emerging countries, rising R&D activities for biomarker detection, and the increasing focus on vaccine development are expected to generate market growth opportunities. However, stringent regulations for ELISA product approval and the availability and usage of alternative technologies for disease diagnosis are major challenges in the ELISA market.
The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry in the past three to four years. The key players operating in the ELISA market are Thermo Fisher Scientific Inc. (U.S.), Merck KGaA (Germany), Bio-Rad Laboratories Inc. (U.S.), F. Hoffmann-La Roche AG (Switzerland), Danaher Corporation (U.S.), QIAGEN N.V. (Netherlands), Agilent Technologies, Inc. (U.S.), Abbott Laboratories (U.S.), bioMerieux SA (France), Revvity Inc. (U.S.), QuidelOrtho Corporation (U.S.), Becton, Dickinson and Company (U.S.), Repligen Corporation (U.S.), BioLegend (U.S.), and Bio-Techne Corporation (U.S.).
Among all the ELISA types studied in this report, in 2024, the indirect ELISA segment is expected to account for the largest share of 43.5% of the ELISA market. The largest share of this segment is attributed to the highly sensitive nature of indirect ELISA and the ability of ELISA to identify antigens in low-concentration solutions and the advantages of the indirect ELISA methods such as cost-effectiveness, easy operation, and most preferable for all applications. The indirect method helps in disease diagnoses such as Lyme disease and HIV, which minimizes the possibility of false positive results.
Among all the ELISA offerings studied in this report, in 2024, the kits & assays segment is expected to account for the largest share of 85.2% of the ELISA market. The larger market share of this segment is attributed to the increased use of ELISA kits & assays for biomarker detection and several chronic and infectious diseases, the availability of a wide range of assay kits for research purposes, and the wide adoption of ELISA assay kits in drug discovery.
Among all the technologies studied in this report, in 2024, the colorimetric ELISA segment is expected to account for the largest share of the ELISA market. Colorimetric ELISA is widely preferred due to its advantages such as low reagent consumption, simplicity, cost-effectiveness, broad range of applications, ease of performance, and requirement of less equipment to process. Additionally, these assays are compatible with various types of samples for complex research.
Among all the applications studied in this report, in 2024, the diagnostic applications segment is expected to account for a larger share of the ELISA market. ELISA is widely used in clinical settings for the identification of infectious diseases, allergies, cancer, autoimmune diseases, and drug discovery. High demand for ELISA kits for disease diagnosis and high adoption of self-testing pregnancy kits due to their wide availability in pharmacies at low prices support the largest share of the market.
Among all the end users studied in this report, in 2024, the diagnostic laboratories segment is expected to account for a larger share of the ELISA market. The segment's largest share is attributed to the high burden of chronic diseases, the rising number of diagnostic laboratories, and supportive initiatives to advance clinical testing capabilities in countries. For instance, according to the Science and Medicine Group (U.S.), in July 2024, Danaher announced the launch of CLIA and College of American Pathologists-certified labs for research and development in companion diagnostics and complementary diagnostics. The first two labs will be opened in Newcastle, the U.K., and the second lab will be opened in the U.S.
An in-depth analysis of the geographical scenario of the ELISA market provides detailed qualitative and quantitative insights into the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. North America is expected to account for the largest share of 37.7% of the ELISA market. The large share of this regional market is attributed to the well-established healthcare infrastructure, high investment in R&D activities, high prevalence of chronic diseases, a large number of diagnostic and pathology laboratories, and the presence of key market players in the region. For instance, in December 2022, Labcorp (U.S.) launched an anatomic pathology and histology (APH) laboratory in Los Angeles, the U.S.
ELISA Market Assessment-by Type
ELISA Market Assessment-by Offering
ELISA Market Assessment-by Technology
ELISA Market Assessment-by Application
Note: Other drug discovery & monitoring applications include toxicology studies and quality control.
Note: Other diagnostics applications include allergen testing and pregnancy testing.
Note: Other applications include agricultural, environmental, veterinary, and forensic applications.
ELISA Market Assessment-by End User
Note: Other end users include home healthcare, the agriculture industry, and the forensics industry.
ELISA Market Assessment-by Geography
(Note: SWOT analysis will be provided for the top 5 companies.)